A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of Avelumab (MSB0010718C) in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications

Trial ID # NCT01772004
Phase I
Drug Class Immunotherapy: Checkpoint Inhibitors/PD-L1
Drug Name Avelumab
Alternate Drug Names Anti programmed death ligand 1 monoclonal antibody, Anti-PD-L1, MSB0010718C, Bavencio
Drugs in Trial Avelumab
Eligible Participant

Metastatic or Locally Advanced Solid Tumors

Patients Enrolled

1670 [125 ovarian; median 3 prior therapies (1-10)]

Therapy Setting


Study Design

Open-Label, Non-randomized


ORR, DCR, DoR, PFS, OS, evaluated per RECIST


Exploratory: BRCA1/2, PD-L1 protein


ORR: 9.6% (1CR, 11PR, n=125)
DCR: 52.0% (1CR, 11PR, 53SD, n=125)
PFS: 2.6 months (1.4-2.8)
DoR: 10.4 months (4.2-NA)
OS: 11.2 months (8.7-15.4)

Exploratory analysis: PD-L1 levels, BRCA status):
No disease related parameter was associated with response to Ave

Clinically Significant Adverse Events

Serious AE: none
Grade 3-4 AE: 7.2% (9/125)


Encouraging activity with acceptable safety profile


Disis, ML et al. Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial. Jama Oncol (2019) 5(3):393-401

Contact Us
Contact Us

We are here to help! Send us a message below or give us a call at (858) 657-0282.